Statistics

Total Visits

Views
AVALUZ study: First line with bevacizumab in combination with paclitaxel (P) and gemcitabine (G) in patients with HER-2 negative recurrent or metastatic BC: PFS analysis13

Select a period of time:

Number of views in the range

Views
AVALUZ study: First line with bevacizumab in combination with paclitaxel (P) and gemcitabine (G) in patients with HER-2 negative recurrent or metastatic BC: PFS analysis6

Views

Views
May 20242
June 20243
July 20241
August 20240
September 20240
October 20240
November 20240
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States6
 

Top cities views

Views
Chicago2